Fully biodegradable coronary stents: Progress to date

American Journal of Cardiovascular Drugs

Volumn 8, Issue 5, 2008, Pages 305-314

  Ramcharitar, Steve ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disorders, prevention; Cardiovascular disorders, treatment; Coronary artery restenosis, prevention; Coronary stenting; Drug eluting stents

Indexed keywords

ANTIBODY; ANTIMITOTIC AGENT; BIOPOLYMER; CHROMIUM; COBALT; EVEROLIMUS; MAGNESIUM; METAL; POLYLACTIDE; POLYTYROSINE; SALICYLIC ACID; TYROSINE; UNCLASSIFIED DRUG;

ABSORBABLE MAGNESIUM STENT; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIUM CELL; EPITHELIZATION; HEART INFARCTION; HUMAN; INFLAMMATION; KINETICS; PRIORITY JOURNAL; RESTENOSIS; REVIEW; STEM CELL; STRENGTH;

ABSORBABLE IMPLANTS; ANIMALS; BIOCOMPATIBLE MATERIALS; CLINICAL TRIALS AS TOPIC; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; METALS; POLYMERS; STENTS;

EID: 53149150602     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808050-00003     Document Type: Review

References (47)

1. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006; 354: 483-95
2. Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J 2006; 151: 1194-204
3. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78
4. Serruys PW. ARTS I: the rapamycin eluting stent. ARTS II: the rosy prophecy. Eur Heart J 2002; 23 (10): 757-9.
5. Serruys PW, Daemen J. Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 2007; 115: 1433-9
6. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-97
7. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115: 1051-8
8. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006; 18: 70-4
9. Erne P, Schier M, Resink TJ. The road to bioabsorbable stents: reaching clinical reality? Cardiovasc Intervent Radiol 2006; 29: 11-6
10. Ramcharitar S, Vaina S, Serruys PW. The next generation of drug-eluting stents: what's on the horizon? Am J Cardiovasc Drugs 2007; 7: 81-93
11. Aoki J, Ong AT, Rodriguez Granillo GA, et al. "Full metal jacket" (stented length > or = 64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 2005; 150: 994-9
12. Hoffmann R, Mintz GS, Popma JJ, et al. Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. J Am Coll Cardiol 1996; 28: 1134-9
13. Spuentrup E, Ruebben A, Mahnken A, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation 2005; 111: 1019-26
14. Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv 2007; 69: 1064-74
15. Stack RE, Califf RM, Phillips HR. Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 1988; 62: 3F-24F
16. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-7
17. Venkatraman S, Poh TL, Vinalia T, et al. Collapse pressures of biodegradable stents. Biomaterials 2003; 24: 2105-11
18. Uurto I, Juuti H, Parkkinen J, et al. Biodegradable self-expanding poly-L/D-lactic acid vascular stent: a pilot study in canine and porcine iliac arteries. J Endovasc Ther 2004; 11: 712-8
19. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004; 25: 1330-40
20. Asplund B, Sperens J, Mathisen T, et al. Effects of hydrolysis on a new biodegradable co-polymer. J Biomater Sci Polym Ed 2006; 17: 615-30
21. Gollwitzer H, Thomas P, Diehl P, et al. Biomechanical and allergological characteristics of a biodegradable poly (D,L-lactic acid) coating for orthopaedic implants. J Orthop Res 2005; 23: 802-9
22. Pietrzak WS, Verstynen ML, Sarver DR. Bioabsorbable fixation devices: status for the craniomaxillofacial surgeon. J Craniofac Surg 1997; 8 (2): 92-6
23. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 2000; 21 (23): 2335-46
24. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102: 399-404
25. Tamai H, Igaki K, Tsuji T. A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J Interv Cardiol 1999; 12: 443-50
26. Douek PC, Correa R, Neville R, et al. Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers. Circulation 1992; 86: 1249-56
27. Colombo A, Karvouni E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation 2000; 102: 371-3
28. Tamai H. Biodegradable stents four-year follow-up [presentation]. Complex Coronary Therapeutics; 2004 Oct 21-24; Kobe
29. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998; 32: 780-6
30. Hehrlein C. Promises of biodegradable stents [letter]. Catheter Cardiovasc Interv 2007; 69: 739
31. Shulze J. Biodegradable stent program. Transcatheter and Therapeutics 2004; 2004 Sep 27-Oct 21; Washington, DC
32. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007; 69: 128-31
33. ABBOTT Vascular. ABSORB trial investigator brochure. Santa Clara (CA): ABBOTT Vascular, 2006
34. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the ever-olimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007; 70: 515-23
35. Ormiston JA, Serruys PW, Regar E, et al. First-in-man evaluation of a bioabsorbable-everolimus eluting coronary stent system (BVS) in the treatment of patients with single de-novo native coronary artery lesions: the ABSORB trial. Lancet 2008; 15; 371: 873-4
36. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005; 45: 1574-9
37. Schultz R. The REVA bioabsorbable stent program [slide]. Cardiovascular Revascularization Therapies 2007; 2007 Mar 7-10; Washington, DC [online]. Available from URL: http://www.crtonline.org/flash.aspx?PAGE_ID=4109 [Accessed 2008 Sep 22]
38. Buchbinder M. Biodegradable stents-BTI approach [slide]. Cardiovascular Revascularization Therapies 2007; 2007 Mar 7-10; Washington, DC [online]. Available from URL: http://www.crtonline.org/flash.aspx?PAGE_ID=4112 [Accessed 2008 Sep 22]
39. Jabara R. Initial assessment of a novel anti-inflammatory salicylic acid-based absorbable polymer for use in fully biodegradable coronary stents [slide]. American College of Cardiology (ACC) 2007 and i2 Summit; 2007 Mar 25; New Orleans (LA) [online]. Available from URL: http://media.crtonline.org/ slides/evan_InitialAssessmentofaN_04132007/jabara2.ppt [Accessed 2008 Sep 22]
40. Heublein B, Rohde R, Kaese V, et al. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 2003; 89: 651-6
41. Di Mario C, Griffiths H, Goktekin O, et al. Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 2004; 17: 391-5
42. Peeters P, Bosiers M, Verbist J, et al. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. J Endovasc Ther 2005; 12: 1-5
43. Waksman R, Pakala R, Kuchulakanti PK, et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006; 68: 607-17
44. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-75
45. Waksman R. Absorbable metal stent, clinical update and DREAMS - Drug Eluting Absorbable Metal Stent, concept and pre-clinical data. 2007 ICI Meeting; 2007 Dec 2-4; Tel-Aviv [online]. Available from URL: http://www.congress.co.il/ ici2007/images/ppt2/1400_Waksman_C_Mon.ppt [Accessed 2008 Sep 22]
46. Peuster M, Wohlsein P, Brugmann M, et al. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal results 6-18 months after implantation into New Zealand white rabbits. Heart 2001; 86: 563-9
47. Peuster M, Hesse C, Schloo T, et al. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 2006; 27: 4955-62